Renal effects induced by prolonged mPGES1 inhibition

American Journal of Physiology - Renal Physiology

Volumn 306, Issue 1, 2014, Pages

  Salazar, Francisco ^a   Vazquez, Michael L ^b   Masferrer, Jaime L ^b   Mbalaviele, Gabriel ^b   Llinas, Maria T ^a   Saez, Fara ^a   Arhancet, Grace ^b   Salazar, F Javier ^a  

^a UNIVERSITY OF MURCIA   (Spain)

^b PFIZER INC   (United States)

Author keywords

Membrane bound prostaglandin E synthase 1; Renal hemodynamics; Sodium diet

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 6 OXOPROSTAGLANDIN F1 ALPHA; ALDOSTERONE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; INDOMETACIN; MEMBRANE BOUND PROSTAGLANDIN E SYNTHASE 1; MEMBRANE ENZYME; PF 458; PROSTAGLANDIN D2; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN SYNTHASE INHIBITOR; RENIN; THROMBOXANE B2; UNCLASSIFIED DRUG; [1 [5 CHLORO 6 (4 CHLOROPHENYL)BENZO[D]OXAZOL 2 YL] N [ 4 (HYDROXYMETHYL)CYCLOHEXYL]PIPERADINE 4 CARBOZAMIDE];

ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME SYNTHESIS; EXPERIMENTAL DOG; GLOMERULUS FILTRATION RATE; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SODIUM INTAKE; URINALYSIS; URINARY EXCRETION;

EID: 84891503414     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00492.2013     Document Type: Article

References (29)

1. Alderman MH, Piller LB, Ford CE, Probstfield JL, Oparil S, Cushman WC, Einhorn PT, Franklin SS, Papademetriou V, Ong ST, Eckfeldt JH, Furberg CD, Calhoun DA, Davis BR; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihyper-tensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 59: 926-933, 2012.
2. Arhancet GB, Walker DP, Metz S, Fobian YM, Heasley SE, Carter JS, Springer JR, Jones DE, Hayes MJ, Shaffer AF, Jerome GM, Baratta MT, Zweifel B, Moore WM, Masferrer JL, Vazquez ML. Discovery and SAR of PF-4693627, a potent, selective and orally bioavailable mPGES-1 inhibitor for the potential treatment of inflammation. Bioorg Med Chem Lett 23: 1114-1119, 2013.
3. Breyer MD, Breyer RM. G protein-coupled prostanoids receptors and the kidney. Annu Rev Physiol 63: 579-605, 2001.
4. Cheng Y, Wang M, Yu Y, Lawson J, Funk CD, Fitzgerald GA. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest 116: 1391-1399, 2006.
5. Facemire CS, Griffiths R, Audoly LP, Koller BH, Coffman TM. The impact of microsomal prostaglandin E synthase 1 on blood pressure is determined by genetic background. Hypertension 55: 531-538, 2010.
6. Francois H, Facemire CS, Kumar A, Audoly L, Koller B, Coffman T. Role of microsomal E synthase 1 in the kidney. J Am Soc Nephrol 18: 1466-1475, 2007.
7. Fuson AL, Komlosi P, Unlap TM, Bell PD, Peti-Peterdi J. Immunolocalization of a microsomal protsglandin E synthase in rabbit kidney. Am J Physiol Renal Physiol 285: F558-F564, 2003.
8. González JD, Llinás MT, Nava E, Ghiadoni L, Salazar FJ. Role of nitric oxide and prostaglandins in the long-term control of renal function. Hypertension 32: 33-38, 1998.
9. Hanlon JT, Schmader KE, Koronowski MJ, Weinberger M, Landsman PB, Samsa GP, Lewis IK. Adverse drug events in high risk older outpatients. J Am Geriatr Soc 45: 945-948, 1997.
10. + exchanger NHE2. Am J Physiol Renal Physiol 294: F937-F944, 2008.
11. Harding P, Yang XP, He Q, LaPointe MC. Lack of microsomal prostaglandin E synthase-1 reduces cardiac function following angiotensin II infusion. Am J Physiol Heart Circ Physiol 300: H1053-H1061, 2011.
12. Howe LR, Subbaramaiah K, Kent CV, Zhou XK, Chang SH, Hla T, Jakobsson PJ, Hudis CA, Dannenberg AJ. Genetic deletion of microsomal prostaglandin E synthase-1 suppresses mouse mammary tumor growth and angiogenesis. Prostaglandins Other Lipid Mediat; http:// dx.doi.org/10.1016/j.prostaglandins.2013.04.002.
13. Jia Z, Aoyagi T, Yang T. mPGES-1 protects against DOCA-salt hypertension via inhibition of oxidative stress or stimulation of NO/cGMP. Hypertension 55: 539-546, 2010.
14. Jia Z, Liu G, Downton M, Dong Z, Zhang A, Yang T mPGES-1 deletion potentiates urine concentrating capability after water deprivation. Am J Physiol Renal Physiol 302: F1005-F1012, 2012.
15. Jia Z, Zhang A, Zhang H, Dong Z, Yang T. Deletion of microsomal prostaglandin E synthase-1 increases sensitivity to salt loading and angiotensin II infusion. Circ Res 99: 1243-1251, 2006.
16. Kurtz A, Wagner C. Cellular control of renin secretion. J Exp Biol 202: 219-225, 1999.
17. Mbalaviele G, Pauley AM, Shaffer AF, Zweifel BS, Mathialagan S, Mnich SJ, Nemirovskiy OV, Carter J, Gierse JK, Wang JL, Vazquez ML, Moore WM, Masferrer JL. Distinction of microsomal prostaglandin E synthase-1 (mPGES-1) inhibition from cyclooxygenase-2 inhibition in cells using a novel, selective mPGES-1 inhibitor. Biochem Pharmacol 79: 1445-1454, 2010.
18. Peti-Peterdi J, Komlosi P, Fuson AL, Guan Y, Schneider A, Qi Z, Redha R, Rosivall L, Breyer M, Bell PD. Luminal NaCl delivery regulates basolateral PGE2 release from macula densa cells. J Clin Invest 76: 76-82, 2003.
19. Radi ZA, Ostroski R. Pulmonary and cardiorenal cyclooxygenase-1 (COX-1),-2 (COX-2), and microsomal prostaglandin E synthase-1 (mPGES-1) and-2 (mPGES-2) expression in a hypertension model. Mediators Inflamm 2007: 1-8, 2007.
20. Roig F, Llinás MT, Lopez R, Salazar FJ. Role of cyclooxygenase-2 in the prolonged regulation of renal function. Hypertension 40: 721-728, 2002.
21. Schneider A, Zhang Y, Zhang M, Lu WJ, Rao R, Fan X, Redha R, Davis L, Breyer R, Harris R, Guan Y, Breyer MD. Membraneassociated PGE synthase-1 (mPGES-1) is coexpressed with both COX-1 and COX-2 in the kidney. Kidney Int 65: 1205-1213, 2004.
22. Salazar F, Salazar FJ, Saez F, Reverte V, Zweifel B, Dufield D, Radabaugh M, Graneto M, Llinas MT, Masferrer JL. Leukotrienes, but not angiotensin II, are involved in the renal effects elicited by the prolonged cyclooxygenase-2 inhibition when sodium intake is low. J Cardiovasc Pharmacol 61: 329-336, 2013.
23. Schlondorff D. Renal complications of nonsteroidal anti-inflammatory drugs. Kidney Int 44: 643-653, 1993.
24. Soler M, Camacho M, Escudero JR, Iniguez MA, Vila L. Human vascular smooth muscle cells but not endothelial cells express prostaglandin E synthase. Circ Res 87: 504-507, 2000.
25. Trebino CE, Stock JL, Gibbons CP, Naiman BM, Wachtmann TS, Umland JP, Pandher K, LaPointe JM, Saha S, Roach ML, Carter D, Thomas NA, Durtschi BA, McNeish JD, Hambor JE, Jakobsson PJ, Carty TJ, Perez JR, Audoly LP. Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc Natl Acad Sci USA 100: 9044-9049, 2003.
26. Vizthum H, Abt I, Einhellig S, Kurtz A. Gene expression of prostanoid forming enzymes along the rat nephron. Kidney Int 62: 1570-1581, 2002.
27. Watanabe K. Prostaglandin F synthase. Prostaglandins Other Lipid Mediat 68-69: 401-407, 2002.
28. Zhang DJ, Chen LH, Zhang YH, Yang GR, Dou D, Gao YS, Zhang XY, Kong XM, Zhao P, Pu D, Wei MF, Breyer MD, Guan YF. Enhanced pressor response to acute Ang II infusion in mice lacking membrane-associated prostaglandin E2 synthase-1. Acta Physiol Sinica 31: 1284-1292, 2010.
29. Zweifel BS, Hardy MM, Anderson GD, Dufield DR, Pufahl RA, Masferrer JL. A rat air pouch model for evaluating the efficacy and selectivity of 5-lipoxygenase inhibitors. Eur J Pharmacol 584: 166-174, 2008.